Skip to Content

FDA Approves Glumetza

FDA Approves Glumetza for Type 2 Diabetes

Glumetza is a once-daily, extended-release formulation of metformin hydrochloride which may offer potential advantages such as less frequent dosing and fewer side effects. Glumetza is indicated for the treatment of Type 2 diabetes.

Posted: June 2005

Related Articles:

Glumetza (metformin extended release) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.